The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...

Abby Jones’ first stop of the day delivering medication was the home of 90-year-old Sarah Campbell Kier. “Come in!” yelled ...

In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...

The Iowa Pharmacy Association is calling for reform from Iowa lawmakers after 29 pharmacies closed last year, including some ...

A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an ...

A new FTC report blames Pharmacy Benefit Managers for marking up specialty drug prices, profiting $7.3 billion from cancer ...

Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their ...

Pharmacy advocate groups are teaming up with lawmakers to get new legislation passed to stop monopolistic behaviors from ...

US FTC Finds Major Pharmacy Benefit Managers Inflated Drug Prices for $7.3 Billion Gain By Ahmed Aboulenein and Amina Niasse WASHINGTON (Reuters) -The nation's three largest pharmacy benefit ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

That reality is the very reason that's prompting lawmakers to take action against Pharmacy Benefit Managers (PBMs) in hopes of preventing further economic strain on communities. A press conference ...